The FLT3 receptor is activated by juxtamembrane insertion mutations and by activation loop
point mutations in patients with acute myeloid leukemia (AML). In a systematic tyrosine …

Activating mutations of FLT3 have been detected in patients with acute myeloid leukemia
(AML). Two distinct types of FLT3 mutations are most common: internal tandem duplication …

Fms-like tyrosine kinase 3 (FLT3) receptor mutations as internal tandem duplication (ITD) or
within the kinase domain are detected in up to 35% of patients with acute myeloid leukemia …

Constitutively activating FLT3 receptor mutations have been found in 35% of patients with
acute myeloblastic leukemia (AML). Here we report the identification of a small molecule …

Activating length mutations in the juxtamembrane (JM) domain of the FLT3 gene (FLT3-LM)
and mutations in the catalytic domain (FLT3D835/836) of this receptor tyrosine kinase …

Internal tandem duplications (ITD) and D835 point mutations of the receptor tyrosine kinase
(RTK) FLT3 are found in a high proportion of cases with acute myeloid leukemia (AML) …

FLT3, a tyrosine kinase receptor class III (RTK), and its ligand (FL) are important for normal
haematopoiesis and the development of the immune system. Recently, internal tandem …

The receptor tyrosine kinase Flt3 is expressed on leukaemic blasts of most cases with acute
myeloid leukaemia (AML). In order to evaluate the presence and significance of constitutive …

FMS-like tyrosine kinase 3 (FLT3), a class III receptor tyrosine kinase, is expressed at high
levels in the blasts of approximately 90% of patients with acute myelogenous leukemia …

Genomic DNA from 97 cases of adult de novo acute myeloid leukaemia (AML) was
screened using polymerase chain reaction (PCR) and conformation‐sensitive gel …